Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2020 - 12 - 17 save search
FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients
Published: 2020-12-17 (Crawled : 22:12) - prnewswire.com
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: 0.06%
H: 0.7%
C: 0.11%
heart fda approval fda approval
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Published: 2020-12-17 (Crawled : 22:01) - biospace.com/
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.3%
H: 0.99%
C: 0.93%
fda approval fda approval biosimilar
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin
Published: 2020-12-17 (Crawled : 22:00) - biospace.com/
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 28.72%
H: 6.2%
C: -10.91%
berubicin approval fda trial phase 2 fda ide
Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA
Published: 2020-12-17 (Crawled : 18:00) - biospace.com/
KRBP | $2.939 -90.21% 320
|
Health Technology
|
| O: -0.33%
H: 95.17%
C: -6.11%
fda therapy submission t-cell car-t application
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Published: 2020-12-17 (Crawled : 15:01) - biospace.com/
BPMC | $85.19 -2.36% -2.42% 510K
|
Health Technology
|
| O: 0.01%
H: 0.78%
C: 0.66%
drug fda treatment new drug application
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 28.72%
H: 6.2%
C: -10.91%
berubicin brain cancer fda approval fda approval cancer drug application train
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in AcneCompany on track to initiate the TRILOGY Phase 3 program in 2021
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
VYNE | $2.57 -7.22% -7.78% 59K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: -3.65%
fda acne phase 3 phase 2
FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Published: 2020-12-17 (Crawled : 14:12) - prnewswire.com
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 1.44%
H: 0.16%
C: -0.19%
fda lupus fda approval
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
MBRX | $4.6269 -5.69% 20K
|
Health Technology
|
| O: 5.13%
H: 0.61%
C: -3.66%
fda
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
Published: 2020-12-17 (Crawled : 13:01) - globenewswire.com
VYNE | $2.57 -7.22% -7.78% 59K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: -3.65%
fda acne phase 2
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Published: 2020-12-17 (Crawled : 02:00) - globenewswire.com
ZLAB | $14.185 -0.87% -0.88% 630K
|
Health Technology
|
| O: 4.86%
H: 0.57%
C: 0.22%
MGNX 4 | $16.95 -3.36% -3.48% 820K
|
Health Technology
|
| O: 11.44%
H: 2.33%
C: -10.52%
fda approval fda approval cancer breast cancer positive her2+ her2- her2
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.